IPO for G1 Therapeutics
- G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer
- G1’s two clinical assets are based on G1’s core understanding of cyclin-dependent kinaseos, or CDKs, a family of proteins that play an important role in the growth and proliferation of all human cells
- G1 has leveraged their deep expertise in CDK4/6 biology to discover and develop two highly potent and selective CDK4/6 inhibitors that may have broad applicability across multiple cancer indications.
- G1 is the only company with two distinct clinical-stage CDK4/6 inhibitors, trilaciclib and G1T38, each of which has the potential to be the backbone therapy of multiple combination regimens.
Key IPO Data
How Does an IPO Work?
Open a Motif Account
Open a brokerage account to get ready for trading.
Participate in an IPO
Review IPO pricing, prospectus, and other documentation.
Place a Conditional Order
Select an investment amount and fund the IPO.